Compare Fox Corp Class A (FOXA) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Travere Therapeutics Inc. Common Stock — how do they compare? Fox Corp Class A trades at $62.63 (market cap $24.93B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Fox Corp Class A is far larger — about 5.1× Travere Therapeutics Inc. Common Stock's market cap, and Fox Corp Class A pays a 0.93% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 35 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FOXA | TVTX | |
|---|---|---|
Market Cap | $24.93B | $4.88B |
Volume | 2,221,953 | 1,668,577 |
Sector | Media | Health |
52-Week High | $76.11 | $67.52 |
52-Week Low | $48.79 | $26.79 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | $28.30B | $5.01B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fox Corporation (FOXA) trades at $62.50, down slightly by 0.14% with a bearish technical signal. The company shows strong fundamentals with revenue growth from $14.0B in 2024 to $16.3B in 2025 and consistent earnings beats. Analyst consensus is bullish with a $72.00 price target, though the pending $22B Roku acquisition faces DOJ scrutiny. Cash flow improved significantly to $1.03B net in 2025, while 2026 projections show potential pressure.
FOXA presents a compelling value opportunity with reasonable valuations (P/E 16.3) and strong profitability (ROE 14.29%). The Roku deal represents both growth potential and regulatory risk. With zero sell ratings and insider buying, institutional sentiment remains positive despite technical weakness. Key risks include integration challenges and advertising market volatility.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
